» Articles » PMID: 39680587

Geographical Mapping and Temporal Trends of Acinetobacter Baumannii Carbapenem Resistance: A Comprehensive Meta-analysis

Overview
Journal PLoS One
Date 2024 Dec 16
PMID 39680587
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) is of critical concern in healthcare settings, leading to limited treatment options. In this study, we conducted a comprehensive meta-analysis to assess the prevalence of CRAB by examining temporal, geographic, and bias-related variations.

Methods: We systematically searched prominent databases, including Scopus, PubMed, Web of Science, and EMBASE. Quality assessment was performed using the JBI checklist. Subgroup analyses were performed based on the COVID-19 timeframes, years, countries, continents, and bias levels, antimicrobial susceptivity test method and guidelines.

Results: Our comprehensive meta-analysis, which included 795 studies across 80 countries from 1995 to 2023, revealed a surge in carbapenem resistance among A. baumannii, imipenem (76.1%), meropenem (73.5%), doripenem (73.0%), ertapenem (83.7%), and carbapenems (74.3%). Temporally, 2020-2023 witnessed significant peaks, particularly in carbapenems (81.0%) and meropenem (80.7%), as confirmed by meta-regression, indicating a steady upward trend.

Conclusion: This meta-analysis revealed an alarmingly high resistance rate to CRAB as a global challenge, emphasizing the urgent need for tailored interventions. Transparency, standardized methodologies, and collaboration are crucial for the accurate assessment and maintenance of carbapenem efficacy.

Citing Articles

Development of a multi-epitope vaccine against Acinetobacter baumannii: A comprehensive approach to combating antimicrobial resistance.

Beig M, Sholeh M, Moradkasani S, Shahbazi B, Badmasti F PLoS One. 2025; 20(3):e0319191.

PMID: 40063635 PMC: 11892874. DOI: 10.1371/journal.pone.0319191.


Clonality and the Phenotype-Genotype Correlation of Antimicrobial Resistance in Isolates: A Multicenter Study of Clinical Isolates from Romania.

Pana A, Schiopu P, Toc D, Neculicioiu V, Butiuc-Keul A, Farkas A Microorganisms. 2025; 13(1).

PMID: 39858944 PMC: 11767935. DOI: 10.3390/microorganisms13010176.

References
1.
Kaur A, Singh S . Prevalence of Extended Spectrum Betalactamase (ESBL) and Metallobetalactamase (MBL) Producing and Isolated from Various Clinical Samples. J Pathog. 2018; 2018:6845985. PMC: 6220378. DOI: 10.1155/2018/6845985. View

2.
Genteluci G, de Souza P, Gomes D, Sousa V, de Souza M, Abib J . Polymyxin B Heteroresistance and Adaptive Resistance in Multidrug- and Extremely Drug-Resistant Acinetobacter baumannii. Curr Microbiol. 2020; 77(9):2300-2306. DOI: 10.1007/s00284-020-02064-6. View

3.
Maspi H, Mahmoodzadeh Hosseini H, Amin M, Fooladi A . High prevalence of extensively drug-resistant and metallo beta-lactamase-producing clinical Acinetobacter baumannii in Iran. Microb Pathog. 2016; 98:155-9. DOI: 10.1016/j.micpath.2016.07.011. View

4.
Smitran A, Lukovic B, Bozic L, Jelic D, Jovicevic M, Kabic J . Carbapenem-Resistant : Biofilm-Associated Genes, Biofilm-Eradication Potential of Disinfectants, and Biofilm-Inhibitory Effects of Selenium Nanoparticles. Microorganisms. 2023; 11(1). PMC: 9865289. DOI: 10.3390/microorganisms11010171. View

5.
Chusri S, Chongsuvivatwong V, Silpapojakul K, Singkhamanan K, Hortiwakul T, Charernmak B . Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect. 2019; 52(5):796-806. DOI: 10.1016/j.jmii.2019.03.004. View